Trial Profile
A prospective, randomized, two-arm, parallel, single-blind, active-controlled, multicentre, non-inferiority clinical study to evaluate the immunogenicity and safety of Hepatitis B Vaccine (rDNA) of M/s Cadila Healthcare Limited compared to Engerix-B of M/s GlaxoSmithKline Biologicals in healthy adult subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Zydus Lifesciences
- 10 Jan 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 13 Nov 2018 New trial record